[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Bonfante et al., 2021 - Google Patents

Mild SARS-CoV-2 infections and neutralizing antibody titers

Bonfante et al., 2021

View PDF
Document ID
16811127891199520541
Author
Bonfante F
Costenaro P
Cantarutti A
Di Chiara C
Bortolami A
Petrara M
Carmona F
Pagliari M
Cosma C
Cozzani S
Mazzetto E
Di Salvo G
Da Dalt L
Palma P
Barzon L
Corrao G
Terregino C
Padoan A
Plebani M
De Rossi A
Donà D
Giaquinto C
Publication year
Publication venue
Pediatrics

External Links

Snippet

BACKGROUND Recent evidence suggests that neutralizing antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 may persist over time; however, knowledge regarding pediatric subjects is limited. METHODS A single-center, prospective observational …
Continue reading at penta-id.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses

Similar Documents

Publication Publication Date Title
Bonfante et al. Mild SARS-CoV-2 infections and neutralizing antibody titers
Demonbreun et al. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.
He et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study
Shioda et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies
Rostad et al. Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C)
Wajnberg et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
Kogevinas et al. Ambient air pollution in relation to SARS-CoV-2 infection, antibody response, and COVID-19 disease: a cohort study in Catalonia, Spain (COVICAT study)
Manisty et al. Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection
Dingens et al. Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak
Lanzieri et al. Seroprevalence of cytomegalovirus among children 1 to 5 years of age in the United States from the National Health and Nutrition Examination Survey of 2011 to 2012
Middleman et al. Duration of protection after infant hepatitis B vaccination series
Sasisekharan et al. Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
Althoff et al. Antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in all of us research program participants, 2 January to 18 March 2020
Taha et al. Association of recent HIV infection and in-utero HIV-1 transmission
Karachaliou et al. Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain
Hofmann et al. Surveillance of recent HIV infections among newly diagnosed HIV cases in Germany between 2008 and 2014
Yau et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis
Levorson et al. A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States
Lejon et al. Gambiense human african trypanosomiasis and immunological memory: effect on phenotypic lymphocyte profiles and humoral immunity
Knies et al. Persistence of humoral response upon SARS‐CoV‐2 infection
Kogevinas et al. Long-term exposure to air pollution and COVID-19 vaccine antibody response in a general population cohort (COVICAT Study, Catalonia)
Joshi et al. Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults
Ujjainiya et al. High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a delta variant surge
Kaplonek et al. Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19
Mahajan et al. Performance of abbott architect, ortho vitros, and euroimmun assays in detecting prior SARS-CoV-2 infection